Role of epidermal growth factor receptor in breast cancer

Hiroko Masuda, Dongwei Zhang, Chandra Bartholomeusz, Hiroyoshi Doihara, Gabriel N. Hortobagyi, Naoto T. Ueno

Research output: Contribution to journalArticle

229 Citations (Scopus)

Abstract

Decades of research in molecular oncology have brought about promising new therapies which are designed to target specific molecules which promote tumor growth and survival. The epidermal growth factor receptor (EGFR) is one of the first identified important targets of these novel antitumor agents. Approximately half of cases of triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC) overexpress EGFR. Thus, EGFR inhibitors for treatment of breast cancer have been evaluated in several studies. However, results so far have been disappointing. One of the reasons for these unexpected results is the lack of biomarkers for predicting which patients are most likely to respond to EGFR inhibitors. Recent studies have shown that EGFR and its downstream pathway regulate epithelial-mesenchymal transition, migration, and tumor invasion and that high EGFR expression is an independent predictor of poor prognosis in IBC. Further, recent studies have shown that targeting EGFR enhances the chemosensitivity of TNBC cells by rewiring apoptotic signaling networks in TNBC. These studies indicate that EGFR-targeted therapy might have a promising role in TNBC and IBC. Further studies of the role of EGFR in TNBC and IBC are needed to better understand the best way to use EGFR-targeted therapy-e.g., as a chemosensitizer or to prevent metastases-to treat these aggressive diseases.

Original languageEnglish
Pages (from-to)331-345
Number of pages15
JournalBreast Cancer Research and Treatment
Volume136
Issue number2
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Epidermal Growth Factor Receptor
Triple Negative Breast Neoplasms
Breast Neoplasms
Inflammatory Breast Neoplasms
Epithelial-Mesenchymal Transition
Therapeutics
Antineoplastic Agents
Neoplasms
Biomarkers
Neoplasm Metastasis
Survival
Growth
Research

Keywords

  • Breast cancer
  • EGFR
  • Inflammatory breast cancer
  • Targeted therapy
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012). Role of epidermal growth factor receptor in breast cancer. Breast Cancer Research and Treatment, 136(2), 331-345. https://doi.org/10.1007/s10549-012-2289-9

Role of epidermal growth factor receptor in breast cancer. / Masuda, Hiroko; Zhang, Dongwei; Bartholomeusz, Chandra; Doihara, Hiroyoshi; Hortobagyi, Gabriel N.; Ueno, Naoto T.

In: Breast Cancer Research and Treatment, Vol. 136, No. 2, 11.2012, p. 331-345.

Research output: Contribution to journalArticle

Masuda, H, Zhang, D, Bartholomeusz, C, Doihara, H, Hortobagyi, GN & Ueno, NT 2012, 'Role of epidermal growth factor receptor in breast cancer', Breast Cancer Research and Treatment, vol. 136, no. 2, pp. 331-345. https://doi.org/10.1007/s10549-012-2289-9
Masuda, Hiroko ; Zhang, Dongwei ; Bartholomeusz, Chandra ; Doihara, Hiroyoshi ; Hortobagyi, Gabriel N. ; Ueno, Naoto T. / Role of epidermal growth factor receptor in breast cancer. In: Breast Cancer Research and Treatment. 2012 ; Vol. 136, No. 2. pp. 331-345.
@article{06fd9bbc8a4b475bbe6c92c9bfc42e6c,
title = "Role of epidermal growth factor receptor in breast cancer",
abstract = "Decades of research in molecular oncology have brought about promising new therapies which are designed to target specific molecules which promote tumor growth and survival. The epidermal growth factor receptor (EGFR) is one of the first identified important targets of these novel antitumor agents. Approximately half of cases of triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC) overexpress EGFR. Thus, EGFR inhibitors for treatment of breast cancer have been evaluated in several studies. However, results so far have been disappointing. One of the reasons for these unexpected results is the lack of biomarkers for predicting which patients are most likely to respond to EGFR inhibitors. Recent studies have shown that EGFR and its downstream pathway regulate epithelial-mesenchymal transition, migration, and tumor invasion and that high EGFR expression is an independent predictor of poor prognosis in IBC. Further, recent studies have shown that targeting EGFR enhances the chemosensitivity of TNBC cells by rewiring apoptotic signaling networks in TNBC. These studies indicate that EGFR-targeted therapy might have a promising role in TNBC and IBC. Further studies of the role of EGFR in TNBC and IBC are needed to better understand the best way to use EGFR-targeted therapy-e.g., as a chemosensitizer or to prevent metastases-to treat these aggressive diseases.",
keywords = "Breast cancer, EGFR, Inflammatory breast cancer, Targeted therapy, Triple-negative breast cancer",
author = "Hiroko Masuda and Dongwei Zhang and Chandra Bartholomeusz and Hiroyoshi Doihara and Hortobagyi, {Gabriel N.} and Ueno, {Naoto T.}",
year = "2012",
month = "11",
doi = "10.1007/s10549-012-2289-9",
language = "English",
volume = "136",
pages = "331--345",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Role of epidermal growth factor receptor in breast cancer

AU - Masuda, Hiroko

AU - Zhang, Dongwei

AU - Bartholomeusz, Chandra

AU - Doihara, Hiroyoshi

AU - Hortobagyi, Gabriel N.

AU - Ueno, Naoto T.

PY - 2012/11

Y1 - 2012/11

N2 - Decades of research in molecular oncology have brought about promising new therapies which are designed to target specific molecules which promote tumor growth and survival. The epidermal growth factor receptor (EGFR) is one of the first identified important targets of these novel antitumor agents. Approximately half of cases of triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC) overexpress EGFR. Thus, EGFR inhibitors for treatment of breast cancer have been evaluated in several studies. However, results so far have been disappointing. One of the reasons for these unexpected results is the lack of biomarkers for predicting which patients are most likely to respond to EGFR inhibitors. Recent studies have shown that EGFR and its downstream pathway regulate epithelial-mesenchymal transition, migration, and tumor invasion and that high EGFR expression is an independent predictor of poor prognosis in IBC. Further, recent studies have shown that targeting EGFR enhances the chemosensitivity of TNBC cells by rewiring apoptotic signaling networks in TNBC. These studies indicate that EGFR-targeted therapy might have a promising role in TNBC and IBC. Further studies of the role of EGFR in TNBC and IBC are needed to better understand the best way to use EGFR-targeted therapy-e.g., as a chemosensitizer or to prevent metastases-to treat these aggressive diseases.

AB - Decades of research in molecular oncology have brought about promising new therapies which are designed to target specific molecules which promote tumor growth and survival. The epidermal growth factor receptor (EGFR) is one of the first identified important targets of these novel antitumor agents. Approximately half of cases of triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC) overexpress EGFR. Thus, EGFR inhibitors for treatment of breast cancer have been evaluated in several studies. However, results so far have been disappointing. One of the reasons for these unexpected results is the lack of biomarkers for predicting which patients are most likely to respond to EGFR inhibitors. Recent studies have shown that EGFR and its downstream pathway regulate epithelial-mesenchymal transition, migration, and tumor invasion and that high EGFR expression is an independent predictor of poor prognosis in IBC. Further, recent studies have shown that targeting EGFR enhances the chemosensitivity of TNBC cells by rewiring apoptotic signaling networks in TNBC. These studies indicate that EGFR-targeted therapy might have a promising role in TNBC and IBC. Further studies of the role of EGFR in TNBC and IBC are needed to better understand the best way to use EGFR-targeted therapy-e.g., as a chemosensitizer or to prevent metastases-to treat these aggressive diseases.

KW - Breast cancer

KW - EGFR

KW - Inflammatory breast cancer

KW - Targeted therapy

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84868208974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868208974&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2289-9

DO - 10.1007/s10549-012-2289-9

M3 - Article

C2 - 23073759

AN - SCOPUS:84868208974

VL - 136

SP - 331

EP - 345

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -